Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division

Executive Summary

As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.


Related Content

Perrigo Ends 2017 As It Started: Earnings Results Delayed
Perrigo Taps CEO With Global Operations Expertise At Pharma Packaging Firm
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo
Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues
Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts